Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | Outperform → Perform | Oppenheimer | |
| 2/28/2025 | Outperform → Mkt Perform | Barrington Research | |
| 2/13/2025 | $95.00 | Equal Weight | Wells Fargo |
| 10/15/2024 | $96.00 | Neutral | Cantor Fitzgerald |
| 8/2/2024 | $85.00 → $105.00 | Buy | Lake Street |
| 5/31/2024 | $100.00 | Buy | ROTH MKM |
| 4/26/2024 | $59.00 → $75.00 | Hold → Buy | Stifel |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets |
Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform
Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform
Wells Fargo initiated coverage of Lemaitre Vascular with a rating of Equal Weight and set a new price target of $95.00
Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and
BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results Sales $55.7mm, +14% (+14% organic) vs. Q4 2023Gross margin 69.3%, +121 bpsOp. income $12.9mm, +26%Op. margin 23%Earnings per diluted share $0.49, +30%Cash up $175.8mm sequentially to $299.7mm Grafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin im
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, a
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results Sales $54.8mm, +16% (+16% organic) vs. Q3 2023Gross margin 67.8%, +280 bpsOp. income $13.1mm, +43%Op. margin 24%Earnings per diluted share $0.49, +46%Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth. APAC sales increased 24%, EMEA 22% and the Americas 12%. The gross margin increased to 67.8% (vs. 65.0% in Q3 2023), driven by price increases and manufacturing efficiencie
SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that management will be participating in three upcoming investor conferences in March. 37th Annual ROTH ConferenceMonday, March 17, 2025The Laguna Cliffs Marriott, Dana Point, CAManagement will present at 4:00 PM PDT KeyBanc Healthcare ForumWednesday, March 19, 2025Virtual EventManagement will present at 1:30 PM EDT Oppenheimer 35th Annual Healthcare MedTech & Services ConferenceThursday, March 20, 2025Virtual EventManagement will present at 10:00 AM EDT About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular dis
BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results Sales $55.7mm, +14% (+14% organic) vs. Q4 2023Gross margin 69.3%, +121 bpsOp. income $12.9mm, +26%Op. margin 23%Earnings per diluted share $0.49, +30%Cash up $175.8mm sequentially to $299.7mm Grafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin im
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, a
10-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)